mln3126
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2013 (NCT02447458)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C-C chemokine receptor type 9ANTAGONIST
CCR9 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545268 ↗
Also known as
- mln3126
- mln3126
- mln-3126
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02209506 | Phase 1 | Jul 1, 2014 | Takeda |
| NCT02447458 | Phase 1 | Sep 1, 2013 | Takeda |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 2 | 2 | 1 | 2013 |
1 organizations
Page 1 / 1